Histogen 

$0.21
28
+$0.01+4.48% Friday 18:17

Statistik

Harga Tertinggi Hari Ini
0.21
Harga Terendah Hari Ini
0.21
52M Tinggi
1.05
52M Rendah
0.05
Volume
287
Rata-Rata Volume
16,688
Kap Pasar
897,069
Rasio P/E
-0.07
Hasil Dividen
-
Dividen
-

Pendapatan

9NovDikonfirmasi
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
-1.7
-1.2
-0.7
-0.2
EPS yang Diharapkan
-0.54
EPS Aktual
-0.9

Orang Juga Mengikuti

Daftar ini didasarkan pada daftar pantauan orang-orang di Stock Events yang mengikuti HSTO. Ini bukan rekomendasi investasi.

Peserta

Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.

Tentang

Health Technology
Biotechnology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Show more...
CEO
Steven Mento
Karyawan
7
Negara
US
ISIN
US43358Y2028
WKN
000A3DMJS

Daftar